Jana Epprecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Jana Epprecht has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
Michelle Frank
Department of Cardiology, University Hospital Zurich and University of Zurich , Zurich
8 shared publications- Barbara Hasse
Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich and University of Zurich , Zurich
7 shared publications Benoit Guery
Infectious Diseases Service, Lausanne University Hospital and University of Lausanne , Lausanne
7 shared publications- Georgios Tzimas
Department of Cardiology, Lausanne University Hospital and University of Lausanne , Lausanne
7 shared publications - Matthaios Papadimitriou-Olivgeris
Infectious Diseases Service, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland
7 shared publications - Omer Dzemali
Department of Cardiac Surgery, University Hospital Zurich and University of Zurich , Zurich
7 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Mind the Gap: Inadequate Performance of Embolic Risk Scores in Infective Endocarditis
Background: Embolic events (EEs) are frequent and clinically important complications of infective endocarditis (IE). Three scores have been developed to predict EEs: the Embolic Risk French Calculator (for EEs occurring after treatment initiation), and the Italian Endocarditis Study and University of Campania “L. Vanvitelli” Napoli Score (for EEs occurring before or after antimicrobial initiation). This study aimed to externally validate and compare the predictive performance of these scores. Methods: This is a multicenter retrospective study including adult patients diagnosed with IE between 2014 and 2024 at Lausanne University Hospital and University Hospital Zurich. Embolic events and IE were defined according to the 2023 International Society of Cardiovascular Infectious Diseases (ISCVID) Duke criteria. Scores were applied according to their respective populations, and performance was evaluated using sensitivity, specificity, and accuracy. Results: Among 1331 IE episodes, 674 (51%) experienced EEs, with 474 (36%) before and 348 (26%) after antimicrobial initiation. The Embolic Risk French Calculator, applied to 1201 valve-related IE episodes, identified 358 (30%) as high risk. Accuracy for predicting postantibiotic EEs was 66% (95% CI 64%–69%). The Italian Endocarditis Study score, applied to 1073 episodes with left-side IE, classified 563 (53%) as intermediate/high risk, with an overall accuracy of 60% (56%–62%). The University of Campania score, applied to 701 valve-related IE episodes, identified 341 (49%) as intermediate/high risk, with an accuracy of 63% (60%–67%). Conclusions: All 3 scores demonstrated limited predictive accuracy and frequently misclassified patients. More robust tools are needed to guide embolic risk stratification in clinical practice.
- 28 April 2026
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (5)
Open AccessMind the Gap: Inadequate Performance of Embolic Risk Scores in Infective Endocarditis
Background: Embolic events (EEs) are frequent and clinically important complications of infective endocarditis (IE). Three scores have been developed to predict EEs: the Embolic Risk French Calculator (for EEs occurring after treatment initiation), and the Italian Endocarditis Study and University of Campania “L. Vanvitelli” Napoli Score (for EEs occurring before or after antimicrobial initiation). This study aimed to externally validate and compare the predictive performance of these scores. Methods: This is a multicenter retrospective study including adult patients diagnosed with IE between 2014 and 2024 at Lausanne University Hospital and University Hospital Zurich. Embolic events and IE were defined according to the 2023 International Society of Cardiovascular Infectious Diseases (ISCVID) Duke criteria. Scores were applied according to their respective populations, and performance was evaluated using sensitivity, specificity, and accuracy. Results: Among 1331 IE episodes, 674 (51%) experienced EEs, with 474 (36%) before and 348 (26%) after antimicrobial initiation. The Embolic Risk French Calculator, applied to 1201 valve-related IE episodes, identified 358 (30%) as high risk. Accuracy for predicting postantibiotic EEs was 66% (95% CI 64%–69%). The Italian Endocarditis Study score, applied to 1073 episodes with left-side IE, classified 563 (53%) as intermediate/high risk, with an overall accuracy of 60% (56%–62%). The University of Campania score, applied to 701 valve-related IE episodes, identified 341 (49%) as intermediate/high risk, with an accuracy of 63% (60%–67%). Conclusions: All 3 scores demonstrated limited predictive accuracy and frequently misclassified patients. More robust tools are needed to guide embolic risk stratification in clinical practice.
- Open Access
- 31 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Reassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke Clinical Criteria for Infective Endocarditis: Impact of Excluding Fever and Updating Diagnostic Definitions
Background: Fever has traditionally been included as a minor criterion in the Duke criteria for the diagnosing infective endocarditis (IE). We evaluated the diagnostic impact of excluding fever as a minor criterion within the 2023 Duke-ISCVID (International Society for Cardiovascular Infectious Diseases) framework. Methods: We conducted a retrospective study of suspected IE at 2 Swiss University Hospitals (2014–2024). The reference standard was the final diagnosis by the Endocarditis Team or expert clinicians. Each episode was classified using 2 versions of the 2023 Duke-ISCVID criteria: one including and one excluding fever as a minor criterion with updated definitions for definite, possible, and rejected IE. Diagnostic performance was assessed using 2 dichotomizations: in the first analysis, definite IE was considered positive and possible or rejected was negative; in the second, definite or possible IE was positive and rejected was negative. Results: Infective endocarditis was diagnosed in 1331/3694 (36%) episodes. Fever was present in 78% of episodes, with similar prevalence in IE and non-IE episodes (78% vs 77%; P = .484). Using the first evaluation, sensitivity increased modestly from 74% (95% CI: 71%–76%) with the original criteria to 77% (74%–79%) after excluding fever and updating definitions. Using the second evaluation, specificity markedly improved from 49% (47%–51%) to 80% (78%–82%) with these modifications. Conclusions: Exclusion of fever as a minor criterion within the updated Duke-ISCVID framework substantially improved specificity without compromising sensitivity. These findings challenge the traditional role of fever in IE diagnosis and support a broader reevaluation of long-standing diagnostic criteria.
- 31 December 2025
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessReassessing the 2023 International Society for Cardiovascular Infectious Diseases Duke Clinical Criteria for Infective Endocarditis: Impact of Excluding Fever and Updating Diagnostic Definitions
Background: Fever has traditionally been included as a minor criterion in the Duke criteria for the diagnosing infective endocarditis (IE). We evaluated the diagnostic impact of excluding fever as a minor criterion within the 2023 Duke-ISCVID (International Society for Cardiovascular Infectious Diseases) framework. Methods: We conducted a retrospective study of suspected IE at 2 Swiss University Hospitals (2014–2024). The reference standard was the final diagnosis by the Endocarditis Team or expert clinicians. Each episode was classified using 2 versions of the 2023 Duke-ISCVID criteria: one including and one excluding fever as a minor criterion with updated definitions for definite, possible, and rejected IE. Diagnostic performance was assessed using 2 dichotomizations: in the first analysis, definite IE was considered positive and possible or rejected was negative; in the second, definite or possible IE was positive and rejected was negative. Results: Infective endocarditis was diagnosed in 1331/3694 (36%) episodes. Fever was present in 78% of episodes, with similar prevalence in IE and non-IE episodes (78% vs 77%; P = .484). Using the first evaluation, sensitivity increased modestly from 74% (95% CI: 71%–76%) with the original criteria to 77% (74%–79%) after excluding fever and updating definitions. Using the second evaluation, specificity markedly improved from 49% (47%–51%) to 80% (78%–82%) with these modifications. Conclusions: Exclusion of fever as a minor criterion within the updated Duke-ISCVID framework substantially improved specificity without compromising sensitivity. These findings challenge the traditional role of fever in IE diagnosis and support a broader reevaluation of long-standing diagnostic criteria.
- Open Access
- 27 December 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 145, 106682
Risk of endocarditis in patients with bacteraemia by coagulase-negative staphylococci; a multicenter retrospective cohort
- 27 December 2025
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 145, 106682
Open AccessRisk of endocarditis in patients with bacteraemia by coagulase-negative staphylococci; a multicenter retrospective cohort
- Open Access
- 23 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Prediction Scores Identifying Patients at High Risk of Endocarditis in Enterococcal Bacteremia
Background: Clinical prediction scores such as NOVA and DENOVA aim to identify patients with enterococcal bacteremia at low risk of infective endocarditis (IE) in whom imaging might be safely avoided. The aim was to evaluate the performance of NOVA and DENOVA scores and to introduce a modified tool, DENOVi. Method: This retrospective study included adult patients with enterococcal bacteremia at 2 Swiss tertiary centers (2015–2024). IE was adjudicated by multidisciplinary Endocarditis Teams according to 2023 Duke-International Society of Cardiovascular Infectious Diseases criteria. Patients were stratified as high risk for IE using the adapted NOVA score (cutoff: ≥4), the DENOVA score (≥3), and a newly developed DENOVi score (≥2), which excluded the subjective murmur criterion and broadened “valve disease” to include intracardiac electronic devices (new Vi component). Results: Among 827 bacteremia episodes, 172 (21%) were diagnosed with IE. The adapted NOVA, DENOVA, and DENOVi scores classified 76%, 26%, and 42% of patients as high risk, respectively. Corresponding NLRs were 0.04 (95% CI, .01–.15), 0.10 (0.06–0.16), and 0.04 (0.02–0.10). The adapted NOVA substantially increased the proportion of echocardiograms needed to be performed from 58% based on clinical evaluation alone to 76%, whereas the DENOVA and DENOVi scores would have reduced this proportion to 26% and 42% of episodes, respectively. Conclusions: Both adapted NOVA and DENOVi scores reliably ruled out IE, but DENOVi provided the most balanced approach between diagnostic safety and resource utilization. DENOVi therefore represents a pragmatic and objective tool for IE risk stratification in enterococcal bacteremia. Prospective validation is warranted.
- 23 December 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 13 (1)
Open AccessPrediction Scores Identifying Patients at High Risk of Endocarditis in Enterococcal Bacteremia
Background: Clinical prediction scores such as NOVA and DENOVA aim to identify patients with enterococcal bacteremia at low risk of infective endocarditis (IE) in whom imaging might be safely avoided. The aim was to evaluate the performance of NOVA and DENOVA scores and to introduce a modified tool, DENOVi. Method: This retrospective study included adult patients with enterococcal bacteremia at 2 Swiss tertiary centers (2015–2024). IE was adjudicated by multidisciplinary Endocarditis Teams according to 2023 Duke-International Society of Cardiovascular Infectious Diseases criteria. Patients were stratified as high risk for IE using the adapted NOVA score (cutoff: ≥4), the DENOVA score (≥3), and a newly developed DENOVi score (≥2), which excluded the subjective murmur criterion and broadened “valve disease” to include intracardiac electronic devices (new Vi component). Results: Among 827 bacteremia episodes, 172 (21%) were diagnosed with IE. The adapted NOVA, DENOVA, and DENOVi scores classified 76%, 26%, and 42% of patients as high risk, respectively. Corresponding NLRs were 0.04 (95% CI, .01–.15), 0.10 (0.06–0.16), and 0.04 (0.02–0.10). The adapted NOVA substantially increased the proportion of echocardiograms needed to be performed from 58% based on clinical evaluation alone to 76%, whereas the DENOVA and DENOVi scores would have reduced this proportion to 26% and 42% of episodes, respectively. Conclusions: Both adapted NOVA and DENOVi scores reliably ruled out IE, but DENOVi provided the most balanced approach between diagnostic safety and resource utilization. DENOVi therefore represents a pragmatic and objective tool for IE risk stratification in enterococcal bacteremia. Prospective validation is warranted.
- Open Access
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf628
Infective Endocarditis and Antimicrobial Timing: A Case for Delay?
Background: In patients with suspected infective endocarditis (IE), current guidelines recommend prompt initiation of empiric antimicrobial treatment after obtaining blood cultures. However, the clinical benefit of immediate treatment in hemodynamically stable patients remains uncertain. This study assessed the impact of deferring antimicrobial treatment in patients with suspected IE. Methods: We conducted a multicenter cohort study of adult patients with bacteremia and clinical suspicion of IE from 2 university hospitals (2015–24). Patients presenting with sepsis, intensive care unit admission, neutropenia, or a clearly identifiably focus other than IE were excluded. All cases were adjudicated by a dedicated Endocarditis Team as either IE or not IE. The primary outcome for all episodes was 30-day mortality; for confirmed IE cases, the composite outcome included 30-day mortality, new embolic events, or new bone and joint infection. Results: Among 1230 episodes, empirical antimicrobial treatment was initiated immediately (Group I) after blood culture collection in 675 episodes (55%) and deferred until preliminary blood culture results (Group D) in 555 episodes (45%). Thirty-day mortality was 5% (59 episodes), with no difference between Groups I and D (5% vs 5%; P = .894). Of 597 confirmed IE episodes (49%) IE, 327 (55%) were in Group I and 270 (45%) in Group D. The composite primary endpoint occurred in 157 episodes (26%), with no difference between groups (28% vs 24%; P = .304). Conclusions: In clinically stable patients with suspected IE, deferring antimicrobial treatment until available blood culture results was not associated with worse clinical outcomes.
- 29 September 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (10) , ofaf628
Open AccessInfective Endocarditis and Antimicrobial Timing: A Case for Delay?
Background: In patients with suspected infective endocarditis (IE), current guidelines recommend prompt initiation of empiric antimicrobial treatment after obtaining blood cultures. However, the clinical benefit of immediate treatment in hemodynamically stable patients remains uncertain. This study assessed the impact of deferring antimicrobial treatment in patients with suspected IE. Methods: We conducted a multicenter cohort study of adult patients with bacteremia and clinical suspicion of IE from 2 university hospitals (2015–24). Patients presenting with sepsis, intensive care unit admission, neutropenia, or a clearly identifiably focus other than IE were excluded. All cases were adjudicated by a dedicated Endocarditis Team as either IE or not IE. The primary outcome for all episodes was 30-day mortality; for confirmed IE cases, the composite outcome included 30-day mortality, new embolic events, or new bone and joint infection. Results: Among 1230 episodes, empirical antimicrobial treatment was initiated immediately (Group I) after blood culture collection in 675 episodes (55%) and deferred until preliminary blood culture results (Group D) in 555 episodes (45%). Thirty-day mortality was 5% (59 episodes), with no difference between Groups I and D (5% vs 5%; P = .894). Of 597 confirmed IE episodes (49%) IE, 327 (55%) were in Group I and 270 (45%) in Group D. The composite primary endpoint occurred in 157 episodes (26%), with no difference between groups (28% vs 24%; P = .304). Conclusions: In clinically stable patients with suspected IE, deferring antimicrobial treatment until available blood culture results was not associated with worse clinical outcomes.
- Open Access
- 19 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf507
Performance of Different Versions of Duke Criteria in Diagnosing Infective Endocarditis in Patients With Intracardiac Prosthetic Materials
Background: Diagnosing infective endocarditis (IE) is a significant challenge. This study aimed to compare the diagnostic performance of the 2015 and 2023 European Society of Cardiology (ESC) and the 2023 International Society for Cardiovascular Infectious Diseases (ISCVID) Duke clinical criteria in a cohort of patients with suspected IE and intracardiac prosthetic material. Methods: This retrospective study was conducted at 2 Swiss University Hospitals (2014–2024). The reference standard was the diagnosis of the Endocarditis Team or expert clinicians. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. Results: Of the 1025 episodes with suspected IE and intracardiac prosthetic material, 537 (61%) had IE. Using the 2015 ESC, 2023 ESC, and 2023 ISCVID clinical criteria, 324 (32%), 367 (36%), and 430 (42%) episodes were classified as definite IE, respectively. The sensitivity for the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID the clinical criteria was calculated to be 56% (95% CI: 52–60%), 61% (57–65%), and 71% (67–74%), respectively, while the specificity 67% (63–71%), 56% (51–61%), and 34% (29–38%), respectively. Conclusions: The 2023 ISCVID Duke clinical criteria demonstrated the highest sensitivity for diagnosing IE compared to the 2015 and 2023 ESC Duke criteria in patients with intracardiac prosthetic material. However, this was at the expense of specificity.
- 19 August 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (9) , ofaf507
Open AccessPerformance of Different Versions of Duke Criteria in Diagnosing Infective Endocarditis in Patients With Intracardiac Prosthetic Materials
Background: Diagnosing infective endocarditis (IE) is a significant challenge. This study aimed to compare the diagnostic performance of the 2015 and 2023 European Society of Cardiology (ESC) and the 2023 International Society for Cardiovascular Infectious Diseases (ISCVID) Duke clinical criteria in a cohort of patients with suspected IE and intracardiac prosthetic material. Methods: This retrospective study was conducted at 2 Swiss University Hospitals (2014–2024). The reference standard was the diagnosis of the Endocarditis Team or expert clinicians. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. Results: Of the 1025 episodes with suspected IE and intracardiac prosthetic material, 537 (61%) had IE. Using the 2015 ESC, 2023 ESC, and 2023 ISCVID clinical criteria, 324 (32%), 367 (36%), and 430 (42%) episodes were classified as definite IE, respectively. The sensitivity for the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID the clinical criteria was calculated to be 56% (95% CI: 52–60%), 61% (57–65%), and 71% (67–74%), respectively, while the specificity 67% (63–71%), 56% (51–61%), and 34% (29–38%), respectively. Conclusions: The 2023 ISCVID Duke clinical criteria demonstrated the highest sensitivity for diagnosing IE compared to the 2015 and 2023 ESC Duke criteria in patients with intracardiac prosthetic material. However, this was at the expense of specificity.
- Open Access
- 30 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf408
Evaluation of Different Versions of the Duke Criteria for the Diagnosis of Infective Endocarditis Among Patients With Enterococcal Bacteremia; a Multicenter Study
Background: Enterococci are a common cause of infective endocarditis (IE). This study aimed to assess the diagnostic performance of the 2015 and 2023 Duke versions of the European Society of Cardiology (ESC) Duke criteria, as well as the 2023 Duke International Society of Cardiovascular Infectious Diseases (ISCVID) clinical criteria, for identifying IE among patients with enterococcal bacteremia. Methods: We included adult retrospective patients with enterococcal bacteremia from 3 independent cohorts across 2 Swiss university hospitals between 2015 and 2024. An interdisciplinary Endocarditis Team classified each case as either IE or not IE. Each episode was then classified as definite, possible, or rejected IE according to the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID clinical criteria. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. Results: Among 827 episodes with enterococcal bacteremia, IE was diagnosed in 173 (21%) episodes. The sensitivity of the 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria for diagnosing IE was 67% (95% CI, 59%–74%), 79% (95% CI, 72%–85%), and 74% (95% CI, 67%–80%), respectively. Specificity was 86% (95% CI, 83%–89%) for the 2015 Duke-ESC criteria, 55% (95% CI, 51%–59%) for the 2023 Duke-ISCVID criteria, and 69% (95% CI, 65%–72%) for the 2023 Duke-ESC criteria. Conclusions: Among the evaluated Duke criteria versions, the 2023 Duke-ISCVID criteria demonstrated the highest sensitivity for diagnosing IE in patients with enterococcal bacteremia. However, this was at the expense of specificity.
- 30 June 2025
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 12 (7) , ofaf408
Open AccessEvaluation of Different Versions of the Duke Criteria for the Diagnosis of Infective Endocarditis Among Patients With Enterococcal Bacteremia; a Multicenter Study
Background: Enterococci are a common cause of infective endocarditis (IE). This study aimed to assess the diagnostic performance of the 2015 and 2023 Duke versions of the European Society of Cardiology (ESC) Duke criteria, as well as the 2023 Duke International Society of Cardiovascular Infectious Diseases (ISCVID) clinical criteria, for identifying IE among patients with enterococcal bacteremia. Methods: We included adult retrospective patients with enterococcal bacteremia from 3 independent cohorts across 2 Swiss university hospitals between 2015 and 2024. An interdisciplinary Endocarditis Team classified each case as either IE or not IE. Each episode was then classified as definite, possible, or rejected IE according to the 2015 Duke-ESC, 2023 Duke-ESC, and 2023 Duke-ISCVID clinical criteria. Patients with IE (reference standard) classified as definite IE by the Duke criteria were considered true positives, while those without IE classified as rejected IE were considered true negatives. Results: Among 827 episodes with enterococcal bacteremia, IE was diagnosed in 173 (21%) episodes. The sensitivity of the 2015 Duke-ESC, 2023 Duke-ISCVID, and 2023 Duke-ESC clinical criteria for diagnosing IE was 67% (95% CI, 59%–74%), 79% (95% CI, 72%–85%), and 74% (95% CI, 67%–80%), respectively. Specificity was 86% (95% CI, 83%–89%) for the 2015 Duke-ESC criteria, 55% (95% CI, 51%–59%) for the 2023 Duke-ISCVID criteria, and 69% (95% CI, 65%–72%) for the 2023 Duke-ESC criteria. Conclusions: Among the evaluated Duke criteria versions, the 2023 Duke-ISCVID criteria demonstrated the highest sensitivity for diagnosing IE in patients with enterococcal bacteremia. However, this was at the expense of specificity.
- Open Access
- 6 September 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (10) , 101266
Increase in Oral Streptococcal Endocarditis Among Moderate-Risk Patients
- 6 September 2024
- Published by Elsevier in JACC: Advances
- Vol. 3 (10) , 101266
Open AccessIncrease in Oral Streptococcal Endocarditis Among Moderate-Risk Patients